{
    "2018-04-04": [
        [
            {
                "time": "2018-04-04",
                "original_text": "Health Care Sector Update for 04/04/2018: SNN,AMRN,GSK,LLY",
                "features": {
                    "keywords": [
                        "sector update",
                        "health care",
                        "LLY"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "health care"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-04",
                "original_text": "Why Exelixis Will Triumph In Liver Cancer Battle With Eli Lilly",
                "features": {
                    "keywords": [
                        "Exelixis",
                        "liver cancer",
                        "Eli Lilly"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-04-04",
                "original_text": "Lilly's Cyramza succeeds in late-stage liver cancer trial",
                "features": {
                    "keywords": [
                        "Cyramza",
                        "late-stage",
                        "liver cancer",
                        "trial"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-04",
                "original_text": "Eli Lilly enters collaboration deal with Siligon for diabetes treatment, to take charge for in-process research",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "collaboration",
                        "Siligon",
                        "diabetes",
                        "treatment"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "health care",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-04",
                "original_text": "Eli Lilly and Sigilon Therapeutics Announce Strategic Collaboration to Develop Encapsulated Cell Therapies for the Treatment of Type 1 Diabetes",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Sigilon",
                        "strategic collaboration",
                        "Type 1 Diabetes"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech",
                        "health care"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-04",
                "original_text": "Fast-growing Cambridge biotech Sigilon inks $63M diabetes deal with Eli Lilly",
                "features": {
                    "keywords": [
                        "Cambridge",
                        "biotech",
                        "Sigilon",
                        "diabetes",
                        "deal",
                        "Eli Lilly"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech",
                        "health care"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-04",
                "original_text": "Eli Lilly reports positive results in late-stage trial of liver cancer treatment",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "positive results",
                        "late-stage",
                        "liver cancer",
                        "trial"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-04",
                "original_text": "Lilly Announces CYRAMZAÂ® (ramucirumab) Phase 3 REACH-2 Study in Second-Line Hepatocellular Carcinoma Patients Met Overall Survival Endpoint",
                "features": {
                    "keywords": [
                        "CYRAMZA",
                        "Phase 3",
                        "REACH-2",
                        "Hepatocellular Carcinoma",
                        "Overall Survival"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}